Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis

US10669266B2 · kind B2 · utility

Assignees

• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · US
• University of Kansas · US

Inventors

• John Cijiang He · New Taipei, TW
• Ruijie LIU · New York, US
• Bhaskar C. Das · West Nyack, US
• Wenzhen Xiao · New York, US
• Zhengzhe Li · New York, US
• Kyung LEE · New York, US

Key dates

• Filing date: Jan 5, 2018
• Grant date: Jun 2, 2020
• Expiry date: Jan 5, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N9/99
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure: in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.